Patient info Open main menu

Salvacyl 11.25 mg powder and solvent for suspension for injection – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
11.25 mg
Contains active substance:
Similar medicines:

Patient leaflet - Salvacyl 11.25 mg powder and solvent for suspension for injection

1. What Salvacyl is and what it is used for

Salvacyl contains triptorelin, which is similar to a hormone called gonadotropin releasing hormone (GnRH analogue). It is a long acting formulation designed to slowly deliver 11.25 mg of triptorelin over twelve weeks. It acts by lowering the levels of the male hormone, testosterone, in the body. Salvacyl is used to decrease sexual drive in adult men with severe sexual deviations.

The treatment with Salvacyl is to be initiated and controlled by a psychiatrist. The treatment should be given in combination with psychotherapy, in order to decrease deviating sexual behaviour.

2. What you need to know before you use Salvacyl

Do not use Salvacyl

  • If you suffer from serious osteoporosis (a condition that weakens your bones).
  • If you are allergic to triptorelin, other medicines that regulate the production and release of sex hormones, or any of the other ingredients of this medicine

    (listed in section 6).

Warnings and precautions

At the beginning of treatment there will be an increased amount of testosterone in your body. This might result in an increase in sexual drive. Your doctor may give you some medicine (an anti-androgen) to counteract this effect.

Talk to your doctor:

  • If you develop a depressed mood while taking Salvacyl. There have been reports of depression in patients taking Salvacyl which may be severe. Your doctor may want to monitor your depression during your treatment.
  • If you are using anticoagulants (medicines that inhibit the blood clotting ability), since you may experience bruises at the site of injection.
  • If you are a heavy drinker, a smoker, have osteoporosis (a condition that weakens your bones) or have a family history of osteoporosis, have a poor diet or take anticonvulsants (medicines for epilepsy or fits) or corticosteroids. When Salvacyl is used for a long period of time the risk of developing weak bones is increased, especially if any of the above applies. In order to prevent brittleness of the bones, a healthy lifestyle including no smoking, moderation of alcohol consumption and regular weight bearing exercises that put a load on and strengthens the skeleton, is recommended (e.g. walking, jogging, other forms of sports that put a load on the skeleton). Adequate dietary calcium and vitamin D intake should also be maintained.

  • If you are about to take a diagnostic test of pituitary gonadal function or sex organs. The result can be misleading if you are on Salvacyl treatment or after discontinuation of Salvacyl treatment.
  • If you experience sudden headache, vomiting, problems with eyesight and paralysis of the eye muscles. These can be signs of a benign tumour of the pituitary gland which may be discovered following treatment with Salvacyl.
  • If you have diabetes, or if you suffer from heart or vascular problems
  • If you have any heart or blood vessel conditions, including heart rhythm problems (arrhythmia), or are being treated with medicines for these conditions. The risk of heart rhythm problems may be increased when using Salvacyl.
  • Testosterone decreasing agents may cause changes in ECG associated with heart rhythm abnormalities (QT prolongation).
  • Treatment with GnRH analogues including Salvacyl might increase the risk of anaemia (defined as a decrease in the count of red blood cells). When the treatment is stopped, testosterone will return to normal levels and your sexual drive may increase again. Therefore your doctor may give you another medicine in order to control this effect.

Children and adolescents

Salvacyl is not indicated for use in neonates, infants, children and adolescents.

Other medicines and Salvacyl

When Salvacyl is taken with medicines which affect the release of hormones from the pituitary (part of the brain), your doctor may need to do additional checks. Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Salvacyl might interfere with some medicines used to treat heart rhythm problems (e.g. quinidine, procainamide, amiodarone and sotalol) or might increase the risk of heart rhythm problems when used with some other drugs (e.g. methadone (used for pain relief and part of drug addiction detoxification), moxifloxacin (an antibiotic), antipsychotics used for serious mental illnesses).

Pregnancy, breast-feeding and fertility

Salvacyl is not to be used by women.

Driving and using machines

You may feel dizzy, tired or have problems with your sight such as blurred vision. These are possible side effects of treatment. If you experience any of these side effects you should not drive or use machines.

Salvacyl contains sodium

This medicinal product contains sodium but less than 1 mmol (23 mg) sodium per vial. This medicine is almost ‘sodium-free’ and may be taken with a low sodium diet.

3. How to use Salvacyl

The usual dose is 11.25 mg (one vial) of Salvacyl, given as a single injection into a muscle every twelve weeks.

If you think the effect of Salvacyl is too strong or too weak, contact your doctor.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Many of the side effects are expected, due to the change in the level of testosterone in your body. These effects include hot flushes and impotence. In rare cases (may affect up to 1 in 1,000 people) you may experience a severe allergic reaction and commonly (may affect up to 1 in 10 people) you may experience an allergic reaction. Stop taking Salvacyl and contact a doctor or go to your nearest emergency department immediately if you experience any of the following symptoms: swallowing or breathing problems, swelling of your lips, face, throat or tongue, or a rash.

Other side effects that may occur:

Very common: may affect more than 1 in 10 people:

  • Hot flushes
  • Weakness
  • Excessive sweating
  • Back pain
  • Pins and needles sensation in the legs
  • Reduced libido
  • Impotence

The following information is intended for healthcare professionals only (please see section 3):

1 – PREPARATION OF THE PATIENT BEFORE RECONSTITUTION

  • Prepare the patient by disinfecting his gluteus at the injection site. This operation needs to be performed first because once reconstituted, the drug should be injected immediately.

    2 – PREPARATION OF THE INJECTION

Two needles are provided in the box :

  • Needle 1 : a 20G needle (38mm of length) without safety device to be used for reconstitution
  • Needle 2 : a 20G needle (38mm of length) with safety device to be used for injection

The presence of bubbles on top of the lyophilisate is a normal appearance of the product.

The following steps must be completed in a continuous sequence.

2a

  • Take out the ampoule containing the solvent. Tap any solution within the tip of the ampoule back to the main body of the

    ampoule.

  • Screw Needle 1 (without safety device) on to the syringe. Do not remove the needle protection yet.
  • Break open the ampoule with dot face up.
  • Remove the needle protection from Needle 1. Insert the needle in the ampoule and draw up all the solvent into the syringe.
  • Put aside the syringe containing the solvent.

2b

  • Take out the vial containing the powder; tap any powder which has accumulated at the top of the vial back to the bottom of

    the vial.

  • Remove the plastic tab on the top of vial.
  • Take back the syringe containing the solvent and insert the needle through the rubber stopper vertically into the vial. Inject the

    solvent slowly, so that, if possible, it washes down the entire upper part of the vial.

2c

  • Pull up Needle 1 above the liquid level. Do not remove the needle from the vial. Reconstitute the suspension by swirling gently

    from side to side. Do not invert the vial.

  • Make sure that the agitation is long enough (at least 30 seconds) to obtain a homogeneous and milky suspension.
  • Important: Check there is no unsuspended powder in the vial (if any powder clumps are present, continue swirling until they disappear).

15 Jan 2025

Ipsen

829359

Myriad Pro

Myriad Pro

Nominal Folder Size: 49.5 x 210 mm Folding Instructions: 4 folds - 10 sections

8.0 pt

6.0 pt

Leaflet

495 x 210 mm

1079930

49.5 x 210 mm

LFL SALVACYL 11.25MG GB

BACK / VERSO

Common: may affect up to 1 in 10 people:

  • Nausea, dry mouth
  • Pain, bruising, redness and swelling at injection site, muscle and bone pain; pain in the arms and legs; swelling caused by a build up of fluid in the body tissues, lower abdominal pain,
  • Allergic reaction
  • High blood pressure
  • Increase in weight
  • Dizziness, headache
  • Loss of libido, depression, mood changes

Uncommon: may affect up to 1 in 100 people:

  • Increase in blood platelet count
  • Feeling your heartbeat
  • Ringing in the ears, vertigo (sensation of spinning or whirling motion),
  • Blurred vision
  • Pain in abdomen, constipation, diarrhoea, vomiting
  • Drowsiness, severe shivering associated with sweating and a fever, sleepiness, pain
  • Some blood tests affected (including raised liver function tests),
  • Blood pressure increased
  • Weight loss
  • Loss of appetite, increase of appetite, gout (severe pain and swelling in the joints, usually in the big toe), diabetes, excessive lipids in the blood
  • Joint pain, muscle cramps, muscle weakness, muscle pain, swelling and tenderness, bone pain
  • Tingling or numbness
  • Inability to sleep, irritability
  • Development of enlarged breasts, breast pain, reduction in testicular size, pain in testicles
  • Difficulty in breathing
  • Acne, hair loss, itching, rash, redness of skin, hives
  • The need to wake up to pass urine, problems passing urine
  • Nosebleeds

Rare: may affect up to 1 in 1,000 people:

  • Red or purple discolorations on the skin
  • Abnormal sensation in the eye, or disturbance in vision
  • Distended abdomen (sensation of fullness in the stomach), flatulence, abnormal sense of taste
  • Chest pain
  • Difficulty in standing
  • Flu-like illness, fever
  • Inflammation of the nose/throat
  • Increase in an enzyme present in your body such as bones and liver
  • Increased body temperature
  • Stiff joints, joint swelling, musculoskeletal stiffness, osteoarthritis
  • Memory impairment
  • Feeling confused, decreased activity, having a feeling of elation
  • Shortness of breath when lying flat
  • Blisters
  • Low blood pressure

Not known: frequency cannot be estimated from the available data

  • Changes in ECG (QT prolongation)
  • General discomfort
  • Anxiety
  • Urinary incontinence.
  • If an existing pituitary tumour, an increased risk of bleeding to the area
  • Anaemia (decrease in the count of red blood cells).

An increase in white blood cell count may be found, as with other GnRH analogues, in patients being treated with Salvacyl. Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Salvacyl

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton, vial and ampoule after ‘EXP’. The expiry date refers to the last day of that month. Do not store above 25° C.

Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Salvacyl contains

The active substance is triptorelin.

One vial of powder contains 11.25 mg of triptorelin, as triptorelin embonate.

Reconstituted suspension (2 ml) contains 11.25 mg of triptorelin, as triptorelin embonate.

The other ingredients are:

Powder: poly (d, l-lactide-co-glycolide), mannitol, carmellose sodium and polysorbate 80.

Solvent: water for injection.

What Salvacyl looks like and contents of the pack

Salvacyl is a white to off-white powder.

The solvent is a clear solution.

The package contains:

1 vial with powder

1 ampoule with 2 ml of solvent

1 injection syringe

2 needles.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder

Ipsen Limited

5th Floor, The Point

37 North Wharf Road

Paddington, London

W2 1AF

UK.

Manufacturer

Ipsen Pharma Biotech

Parc d’ Activité du Plateau de signes Chemin Départemental n˚ 402

83870 Signes

France.

This medicinal product is authorised in the Member States of the EEA under the following names: Sweden: Moapar 11.25 mg

Belgium, Germany, Denmark, Finland, Netherlands, United Kingdom, Austria, Ireland and Poland: Salvacyl 11.25 mg France: Salvacyl LP

Norway and Greece: Salvapar

Is this leaflet hard to see or read? Please phone +44 (0) 1753 627777 and ask for help.

This leaflet was last revised in January 2025

2d

  • When the suspension is homogeneous, pull down the needle without inverting the vial, draw up all of the suspension. A small amount will remain in the vial and should be discarded. An overage is included to allow for this loss.
  • Grasp the coloured hub to disconnect the needle. Remove Needle 1 used for the reconstitution from the syringe. Screw on to the syringe Needle 2.
  • Move the safety sheath away from the needle and towards the syringe barrel. The safety sheath remains in the position you set.
  • Remove the needle protection from the needle.
  • Prime the needle to remove air from the syringe and inject immediately.

    3- INTRAMUSCULAR INJECTION

  • To avoid sedimentation, inject immediately into the disinfected area as quickly as possible (within 1 minute from

    reconstitution).

    4 – AFTER USE

  • Activation of the safety system using a one-handed technique.
  • Note: Keep your finger behind the tab at all times.

There are two alternatives to activate the safety system:

  • Method A: push the tab forward with your finger

or

  • Method B: push the sheath to a flat surface.
  • In both cases press down with a firm quick motion until a distinct audible click is heard.
  • Visually confirm that the needle is fully engaged under the lock.
  • Used needles, any unused suspension or other waste material should be disposed of in accordance with local requirements.

    E

    F or

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 34926/0012

Last revision stated in the text: January 2025 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Salvacyl 11.25 mg powder and solvent for suspension for injection

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Triptorelin
Strength 11.25 mg
Pharmaceutical form Powder and solvent for prolonged-release suspension for inj
Powder: White to slightly yellow powder.
Solvent: Clear solution.
How is it taken Intramuscular
Excipients Poly (d, l-lactide-co-glycolide), mannitol, carmellose sodium, polysorbate 80., Water for injection.
Pack sizes 1 vial
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 4 years.
After reconstitution, chemical and physical in- use stability has been demonstrated for 24 hours at 25°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C.
Storage Do not store above 25°C.
For storage conditions after reconstitution of the medicinal product, see section 6.3.
Drug group (ATC) Gonadotrophin releasing hormone analogues
  1. L Antineoplastic and immunomodulating agents
    1. L02 Endocrine therapy antineoplastic and immunomodulating agents
      1. L02A Hormones and related agents
        1. L02AE Gonadotropin releasing hormone analogues, endocrine therapy drugs
          1. L02AE04 triptorelin
Marketing authorisation PL 34926/0012 (first authorised 19 November 2007)
Marketing authorisation holder Ipsen Limited
Codes GTIN 3582186001332 · BNF 08030402

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.